PDGFRB and neoplasm: Khan et al. functionalised optimized imatinib mesylate (competitive inhibitor of ATP binding to Abl kinase, c-Kit, and PDGFR) loaded PLGA nanoparticles with Pluronic® P84, a P-gp inhibitor, to increase therapeutic concentration of drug in the tumor [149,150].